Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 8/2020

25.07.2019 | Original Article

Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database

verfasst von: Huafu Li, Zhewei Wei, Chunming Wang, Wei Chen, Yulong He, Changhua Zhang

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate gender differences in initial presentation, pathology and outcomes with GC (GC).

Methods

The 1973–2013 Surveillance Epidemiology and End Results (SEER) 17-registry database was analysed for renal tumours from 1973 to 2013 coded as primary site “stomach”. After various exclusions, a final study group of 99,922 cases with complete data was obtained. Demographic variables analysed included age, sex, marital status and race. Tumour variables included size, stage at diagnosis, grade, primary site, treatment and histology. Primary outcome variables included overall survival (OS) and cancer-specific survival (CSS).

Results

Overall, 96,501 gastric cancer patients were identified. Of those, 34,862 (36.2%) were women. For woman, log-rank test showed that OS and CSS were significantly longer in man (p < 0.0001). In Cox regression analysis, woman was associated with a significantly improved OS [(HR of death in 1973 to 2003 = 0.87, 95% CI = 0.85–0.89, P < 0.001) (HR of death in 2004 to 2013 = 0.94, 95% CI = 0.91–0.97, P < 0.001)] and cancer-specific survival [(HR of death in 1973 to 2003 = 0.90, 95% CI = 0.87–0.92, P < 0.001) (HR of death in 2004 to 2013 = 0.90, 95% CI = 0.87–0.93, P < 0.001)]. When performing a Kaplan-Meier curve analysis after propensity score matching, gender persisted to be a significant survival of woman for OS and CSS.

Conclusions

Men present with larger, higher stage, higher grade GC than women. OS and CSS are better in women, which is significantly different.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. Jan-Feb 2014;64(1):9–29. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. Jan-Feb 2014;64(1):9–29.
2.
Zurück zum Zitat Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Japanese journal of clinical oncology. Nov 2013;43(11):1157–1158.PubMed Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Japanese journal of clinical oncology. Nov 2013;43(11):1157–1158.PubMed
3.
Zurück zum Zitat Rawicz-Pruszynski K, van Sandick JW, Mielko J, Cisel B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surgical oncology. Dec 2018;27(4):650–656.PubMed Rawicz-Pruszynski K, van Sandick JW, Mielko J, Cisel B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surgical oncology. Dec 2018;27(4):650–656.PubMed
4.
Zurück zum Zitat Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2014;23(5):700–713. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. May 2014;23(5):700–713.
5.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer (Oxford, England : 1990). Apr 2013;49(6):1374–1403. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer (Oxford, England : 1990). Apr 2013;49(6):1374–1403.
6.
Zurück zum Zitat Leoncini E, Vukovic V, Cadoni G, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. European journal of epidemiology. Dec 2018;33(12):1205–1218.PubMedPubMedCentral Leoncini E, Vukovic V, Cadoni G, et al. Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium. European journal of epidemiology. Dec 2018;33(12):1205–1218.PubMedPubMedCentral
7.
Zurück zum Zitat Uhlig A, Seif Amir Hosseini A, Simon J, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis The Journal of urology. Jul 2018;200(1):48–60.PubMed Uhlig A, Seif Amir Hosseini A, Simon J, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis The Journal of urology. Jul 2018;200(1):48–60.PubMed
8.
Zurück zum Zitat Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. The Lancet. Infectious diseases. Oct 2016;16(10):e202-e213.PubMed Fitchett EJA, Seale AC, Vergnano S, et al. Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI): an extension of the STROBE statement for neonatal infection research. The Lancet. Infectious diseases. Oct 2016;16(10):e202-e213.PubMed
9.
Zurück zum Zitat Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. European urology. Jul 2008;54(1):133–140.PubMed Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. European urology. Jul 2008;54(1):133–140.PubMed
10.
Zurück zum Zitat Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. Jun 2000;55(6):876–880.PubMed Mungan NA, Aben KK, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. Jun 2000;55(6):876–880.PubMed
11.
Zurück zum Zitat Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. Jul 2015;18(3):580–589. Song M, Kang D, Yang JJ, et al. Age and sex interactions in gastric cancer incidence and mortality trends in Korea. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. Jul 2015;18(3):580–589.
12.
Zurück zum Zitat Kim HW, Kim JH, Lim BJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Annals of surgical oncology. Dec 2016;23(13):4344–4351.PubMed Kim HW, Kim JH, Lim BJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Annals of surgical oncology. Dec 2016;23(13):4344–4351.PubMed
13.
Zurück zum Zitat Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: a meta-analysis. International journal of cancer. Nov 15 2017;141(10):1942–1949.PubMed Yang Y, Wang G, He J, et al. Gender differences in colorectal cancer survival: a meta-analysis. International journal of cancer. Nov 15 2017;141(10):1942–1949.PubMed
14.
Zurück zum Zitat Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC cancer. Dec 2 2012;12:566.PubMedPubMedCentral Gan L, He J, Zhang X, et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC cancer. Dec 2 2012;12:566.PubMedPubMedCentral
15.
Zurück zum Zitat Fang Z, Zhang T, Dizeyi N, et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. The Journal of biological chemistry.Jan 13 2012;287(3):2090–2098.PubMed Fang Z, Zhang T, Dizeyi N, et al. Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. The Journal of biological chemistry.Jan 13 2012;287(3):2090–2098.PubMed
16.
Zurück zum Zitat Liu X, Gao Y, Ye H, et al. Positive feedback loop mediated by protein phosphatase 1alpha mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic acids research. Apr 20 2017;45(7):3738–3751.PubMedPubMedCentral Liu X, Gao Y, Ye H, et al. Positive feedback loop mediated by protein phosphatase 1alpha mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic acids research. Apr 20 2017;45(7):3738–3751.PubMedPubMedCentral
17.
Zurück zum Zitat Yoshida S, Aihara K, Ikeda Y, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. Jul 2 2013;128(1):60–71.PubMedPubMedCentral Yoshida S, Aihara K, Ikeda Y, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. Jul 2 2013;128(1):60–71.PubMedPubMedCentral
18.
Zurück zum Zitat Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. Aug 1 1999;86(3):547–549.PubMed Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. Aug 1 1999;86(3):547–549.PubMed
19.
Zurück zum Zitat Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. The Journal of pathology. Jan 1999;187(2):237–241.PubMed Koivisto PA, Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. The Journal of pathology. Jan 1999;187(2):237–241.PubMed
20.
Zurück zum Zitat Wu W, Karelia D, Pramanik K, et al. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Molecular carcinogenesis. Aug 2018;57(8):1055–1066.PubMed Wu W, Karelia D, Pramanik K, et al. Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Molecular carcinogenesis. Aug 2018;57(8):1055–1066.PubMed
21.
Zurück zum Zitat Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. The Journal of clinical investigation. Aug 2011;121(8):3159–3175.PubMedPubMedCentral Feng H, Cheng AS, Tsang DP, et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. The Journal of clinical investigation. Aug 2011;121(8):3159–3175.PubMedPubMedCentral
22.
Zurück zum Zitat Grumolato L, Liu G, Haremaki T, et al. beta-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS genetics. 2013;9(8):e1003603.PubMedPubMedCentral Grumolato L, Liu G, Haremaki T, et al. beta-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS genetics. 2013;9(8):e1003603.PubMedPubMedCentral
23.
Zurück zum Zitat Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Statistics in medicine. Sep 10 2010;29(20):2137–2148.PubMedPubMedCentral Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Statistics in medicine. Sep 10 2010;29(20):2137–2148.PubMedPubMedCentral
Metadaten
Titel
Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database
verfasst von
Huafu Li
Zhewei Wei
Chunming Wang
Wei Chen
Yulong He
Changhua Zhang
Publikationsdatum
25.07.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 8/2020
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04304-y

Weitere Artikel der Ausgabe 8/2020

Journal of Gastrointestinal Surgery 8/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.